Related Experiment Videos
Treatment for lupus nephritis: a revisit
Kar Neng Lai1, Sydney C W Tang, Chi Chiu Mok
1Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. knlai@hkucc.hku.hk
Nephrology (Carlton, Vic.)
|May 10, 2005
Summary
Optimal treatment for severe lupus nephritis is uncertain. Mycophenolate mofetil (MMF) shows promise as an effective alternative to cyclophosphamide (CYC), with fewer toxicities for lupus nephritis patients.
Area of Science:
- Nephrology
- Immunology
- Rheumatology
Background:
- Severe lupus nephritis treatment remains unclear.
- Steroid and cyclophosphamide (CYC) are standard but carry significant risks like infection and gonadal toxicity.
- Treatment failure can lead to end-stage renal disease.
Purpose of the Study:
- To evaluate Mycophenolate mofetil (MMF) as an alternative treatment for lupus nephritis.
- To compare the efficacy and safety of MMF against CYC.
- To discuss emerging therapies and trial needs for lupus nephritis.
Main Methods:
- Review of experimental and controlled studies on MMF in lupus nephritis.
- Comparison of MMF's effects on renal remission and flare with CYC.
- Assessment of toxicity profiles, including ovarian toxicity and infection rates.
Main Results:
- MMF demonstrates comparable efficacy to CYC in inducing renal remission and reducing short-term renal flares.
- MMF exhibits significantly lower rates of ovarian toxicity and infection compared to CYC.
- MMF selectively inhibits activated lymphocytes and renal mesangial cells.
Conclusions:
- MMF is a viable and potentially safer alternative for lupus nephritis treatment, especially for patients of reproductive age.
- Reduced toxicity makes MMF an attractive option for lupus nephritis management.
- Future trials are needed to explore ethnicity and histological grading in treatment efficacy.